PE20180556A1 - Anticuerpos inhibidores via del factor tisular y usos de los mismos - Google Patents

Anticuerpos inhibidores via del factor tisular y usos de los mismos

Info

Publication number
PE20180556A1
PE20180556A1 PE2018000267A PE2018000267A PE20180556A1 PE 20180556 A1 PE20180556 A1 PE 20180556A1 PE 2018000267 A PE2018000267 A PE 2018000267A PE 2018000267 A PE2018000267 A PE 2018000267A PE 20180556 A1 PE20180556 A1 PE 20180556A1
Authority
PE
Peru
Prior art keywords
tissue factor
hemophilia
refers
antibodies via
inhibiting antibodies
Prior art date
Application number
PE2018000267A
Other languages
English (en)
Inventor
James R Apgar
Susan Benard
Gregory J Carven
Sunita R Hett
Matthew Holsti
Reema Jasuja
Macy Jin
Zong Sean Juo
Debra Pittman
Mark Stahl
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20180556A1 publication Critical patent/PE20180556A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Referido a un anticuerpo aislado, o fragmento de union a antigeno del mismo, que se une de manera especifica a un epitope en el Dominio Kunitz 2 (K2) del Inhibidor de Via del Factor Tisular (TFPI), e inhiben una actividad del mismo. Tambien se refiere a un metodo para reducir el tiempo de sangrado, que comprende administrar a un sujeto que necesita de la misma, una cantidad terapeuticamente efectiva. Estos son utiles para tratar trastornos hemorragicos y reducir el tiempo de coagulacion, tal es el caso de la hemofilia A, Hemofilia B, Trastorno plaquetario, entre otros.
PE2018000267A 2015-08-19 2016-08-10 Anticuerpos inhibidores via del factor tisular y usos de los mismos PE20180556A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562207229P 2015-08-19 2015-08-19
US201662360205P 2016-07-08 2016-07-08

Publications (1)

Publication Number Publication Date
PE20180556A1 true PE20180556A1 (es) 2018-04-02

Family

ID=56894019

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2023001019A PE20240142A1 (es) 2015-08-19 2016-08-10 Anticuerpos inhibidores via del factor tisular y usos de los mismos
PE2018000267A PE20180556A1 (es) 2015-08-19 2016-08-10 Anticuerpos inhibidores via del factor tisular y usos de los mismos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2023001019A PE20240142A1 (es) 2015-08-19 2016-08-10 Anticuerpos inhibidores via del factor tisular y usos de los mismos

Country Status (21)

Country Link
US (4) US10550200B2 (es)
EP (1) EP3337827A2 (es)
JP (4) JP6664467B2 (es)
KR (4) KR20230074843A (es)
CN (2) CN107922506B (es)
AU (2) AU2016307967C1 (es)
BR (1) BR112018001478A2 (es)
CA (2) CA3174958A1 (es)
CO (1) CO2018001473A2 (es)
IL (3) IL302353A (es)
MX (2) MX2018002048A (es)
MY (1) MY195443A (es)
NZ (1) NZ739871A (es)
PE (2) PE20240142A1 (es)
PH (1) PH12018500211A1 (es)
RU (1) RU2705540C2 (es)
SA (1) SA518390944B1 (es)
SG (1) SG10201912817YA (es)
TW (1) TWI640538B (es)
WO (1) WO2017029583A2 (es)
ZA (1) ZA201800453B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2379600T5 (pl) † 2008-12-22 2021-03-08 Novo Nordisk A/S Przeciwciała przeciwko inhibitorowi szlaku czynnika tkankowego
KR101807894B1 (ko) 2010-03-01 2017-12-12 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
KR20230074843A (ko) * 2015-08-19 2023-05-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
MX2021004120A (es) * 2018-10-11 2021-09-10 Pfizer Regimen de dosificacion para antagonistas de tfpi.
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
US11939373B2 (en) * 2019-09-16 2024-03-26 Opsidio, LLC Anti-stem cell factor antibodies and methods of blocking the interaction between SCF and c-Kit
US20230035617A1 (en) * 2019-11-13 2023-02-02 Pfizer Inc. Stable aqueous anti-tfpi antibody formulation
KR102140653B1 (ko) 2020-01-13 2020-08-03 이선재 떡 연속증숙장치
WO2021231982A1 (en) * 2020-05-14 2021-11-18 City Of Hope Smc1a antibodies and uses thereof
US20240002509A1 (en) * 2020-11-06 2024-01-04 Novartis Ag ANTIBODY Fc VARIANTS
CN113325185B (zh) * 2021-07-09 2024-04-19 重庆鼎润医疗器械有限责任公司 多水平质控品及其制备方法和在血栓弹力图检测上的应用
WO2023118150A1 (en) 2021-12-22 2023-06-29 Royal College Of Surgeons In Ireland A conjugate for use in localising a molecule to the vascular endothelium.
CN117285632A (zh) * 2022-06-17 2023-12-26 安源医药科技（上海）有限公司 针对tfpi的单克隆抗体及其用途
CN116903739B (zh) * 2023-03-28 2023-12-15 中国人民解放军军事科学院军事医学研究院 一种抗s100b蛋白的抗体及其应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
DE69034078T2 (de) 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP1645635A3 (en) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
EP0644946A4 (en) 1992-06-10 1997-03-12 Us Health VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
WO1994012649A2 (en) 1992-12-03 1994-06-09 Genzyme Corporation Gene therapy for cystic fibrosis
DK0695169T3 (da) 1993-04-22 2003-03-17 Skyepharma Inc Multivesikulære liposomer med indkapslet cyclodextrin og farmakologisk aktive forbindelser samt fremgangsmåder til anvendelse af disse
CA2166118C (en) 1993-06-24 2007-04-17 Frank L. Graham Adenovirus vectors for gene therapy
DE69435224D1 (de) 1993-09-15 2009-09-10 Novartis Vaccines & Diagnostic Rekombinante Alphavirus-Vektoren
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
PT797676E (pt) 1993-10-25 2006-05-31 Canji Inc Vector adenoviral recombinante e metodos de utilizacao
RU2160093C2 (ru) 1993-11-16 2000-12-10 Скайефарма Инк. Везикулы с регулируемым высвобождением активных ингредиентов
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
CA2158977A1 (en) 1994-05-09 1995-11-10 James G. Respess Retroviral vectors having a reduced recombination rate
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
WO1997042338A1 (en) 1996-05-06 1997-11-13 Chiron Corporation Crossless retroviral vectors
WO1999018792A1 (en) 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
JP4340339B2 (ja) * 1998-07-31 2009-10-07 財団法人化学及血清療法研究所 血液凝固因子もしくは血液凝固制御因子欠損モデル動物並びに該モデル動物の作製方法
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
EP1575517B1 (en) 2002-12-24 2012-04-11 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2009024653A1 (fr) * 2007-08-23 2009-02-26 Lfb Biotechnologies Anticorps anti-idiotypigues neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii
FR2933908B1 (fr) 2008-07-16 2010-12-24 Renault Sas Dispositif de protection pour une porte de vehicule automobile.
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
JP5739816B2 (ja) * 2008-12-19 2015-06-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉインヒビターおよび使用法
EP2379599B1 (en) 2008-12-22 2015-09-02 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor (tfpi)
PL2379600T5 (pl) * 2008-12-22 2021-03-08 Novo Nordisk A/S Przeciwciała przeciwko inhibitorowi szlaku czynnika tkankowego
CN107693791B (zh) 2010-02-26 2022-06-07 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
KR101807894B1 (ko) * 2010-03-01 2017-12-12 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
NZ603028A (en) * 2010-03-19 2014-11-28 Baxter Healthcare Sa Tfpi inhibitors and methods of use
AU2011257219B2 (en) 2010-05-28 2014-12-04 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
TW201212938A (en) * 2010-06-30 2012-04-01 Novo Nordisk As Antibodies that are capable of specifically binding tissue factor pathway inhibitor
PL2694544T3 (pl) * 2011-04-01 2019-07-31 Bayer Healthcare Llc Przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)
EP2744931B1 (en) 2011-08-18 2018-05-02 Affinity Biosciences Pty Ltd Soluble polypeptides
CN104185474B (zh) 2012-03-30 2017-08-25 拜尔健康护理有限责任公司 蛋白酶调节的抗体
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2014144689A1 (en) 2013-03-15 2014-09-18 Bayer Healthcare Llc Pro-drug antibodies against tissue factor pathway inhibitor
CN105209497B (zh) 2013-03-15 2021-09-07 诺和诺德股份有限公司 能够特异性结合组织因子途径抑制物上的两个表位的抗体
SI2970497T1 (en) 2013-03-15 2018-04-30 Bayer Healthcare Llc Variants of anti-TFPI antibodies with differential binding over the pH range for improved pharmacokinetic properties
EP3022228B1 (en) 2013-07-19 2019-02-27 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
EP3225630B1 (en) 2014-11-27 2021-05-12 Public University Corporation Yokohama City University Method and reagent for detecting ovarian clear cell adenocarcinoma
EP4279128A3 (en) 2015-02-25 2024-02-28 Mogam Institute for Biomedical Research Novel antibody binding to tfpi and composition comprising the same
KR20230074843A (ko) * 2015-08-19 2023-05-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
MX2021004120A (es) 2018-10-11 2021-09-10 Pfizer Regimen de dosificacion para antagonistas de tfpi.

Also Published As

Publication number Publication date
KR102068915B9 (ko) 2023-10-12
RU2705540C2 (ru) 2019-11-07
BR112018001478A2 (pt) 2018-09-18
IL289766B2 (en) 2023-10-01
JP2020096627A (ja) 2020-06-25
CO2018001473A2 (es) 2018-05-10
JP2018527922A (ja) 2018-09-27
AU2016307967B2 (en) 2022-02-17
US11634504B2 (en) 2023-04-25
IL289766B1 (en) 2023-06-01
PE20240142A1 (es) 2024-02-01
SG10201912817YA (en) 2020-02-27
NZ739871A (en) 2022-05-27
RU2018104283A (ru) 2019-09-19
PH12018500211A1 (en) 2018-08-13
IL289766A (en) 2022-03-01
SA518390944B1 (ar) 2022-02-08
JP2024054266A (ja) 2024-04-16
MY195443A (en) 2023-01-21
KR102536303B1 (ko) 2023-05-26
MX2022004834A (es) 2022-05-16
ZA201800453B (en) 2018-12-19
CN107922506B (zh) 2021-11-09
IL302353A (en) 2023-06-01
US20210101998A1 (en) 2021-04-08
WO2017029583A2 (en) 2017-02-23
JP7303761B2 (ja) 2023-07-05
KR102438650B1 (ko) 2022-08-31
US20230416405A1 (en) 2023-12-28
KR102068915B1 (ko) 2020-01-22
CA3174958A1 (en) 2017-02-19
AU2016307967C1 (en) 2023-10-05
US10550200B2 (en) 2020-02-04
TW201718659A (zh) 2017-06-01
WO2017029583A3 (en) 2017-07-20
MX2018002048A (es) 2018-04-13
AU2016307967A1 (en) 2018-02-01
AU2022201091A1 (en) 2022-03-10
US20200190214A1 (en) 2020-06-18
KR20190097319A (ko) 2019-08-20
CN107922506A (zh) 2018-04-17
RU2018104283A3 (es) 2019-09-19
TWI640538B (zh) 2018-11-11
CN114163531A (zh) 2022-03-11
IL256913B (en) 2022-02-01
IL256913A (en) 2018-03-29
KR20230074843A (ko) 2023-05-31
KR20180030936A (ko) 2018-03-26
US20170073428A1 (en) 2017-03-16
JP2022084623A (ja) 2022-06-07
CA2939010A1 (en) 2017-02-19
JP6664467B2 (ja) 2020-03-13
KR20220136381A (ko) 2022-10-07
US10875929B2 (en) 2020-12-29
EP3337827A2 (en) 2018-06-27

Similar Documents

Publication Publication Date Title
PE20180556A1 (es) Anticuerpos inhibidores via del factor tisular y usos de los mismos
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
CL2019001411A1 (es) Métodos para inhibición de la fibrosis en un sujeto en necesidad de ellos. (divisional solicitud 201801817)
CL2018002708A1 (es) Métodos para la inhibición de la angiogénesis en un sujeto que lo necesita
CY1123211T1 (el) Meθοδoi γia th θepaπeytikh antimetωπισh ή thn προληψη thς hmikpaniaς
CL2020002018A1 (es) Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582)
PE20200012A1 (es) Anticuerpos mono- y biespecificos que se unen al factor de coagulacion ix y al factor de coagulacion x
CO2017013356A2 (es) Anticuerpos de factor xi
CR20190403A (es) Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
AR104280A1 (es) Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos
UY37336A (es) Anticuerpos anti-virus del zika y métodos de uso
EA201791168A1 (ru) Способы и составы для лечения сосудистых заболеваний глаз
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων
CO2019006073A2 (es) Estructura cristalina de gremlina 1 y anticuerpo inhibidor
PE20141149A1 (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
EA201992248A1 (ru) АНТИ-C5a-АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
CL2019003485A1 (es) Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909)
EA202192394A1 (ru) Ингибиторы пути передачи сигнала notch и их применение для лечения рака
EA201990988A1 (ru) Антитела против chikv и пути их применения
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
NZ743344A (en) Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
CL2024001421A1 (es) Uso de composición que comprende un anticuerpo anti masp-2 para tratar síndrome de neumonìa idiopàtica.
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp